Close Menu

UNC

The FDA has also granted emergency use authorization for PCR-based tests for SARS-CoV-2 developed by Orig3n, Specialty Diagnostic Laboratories (SDI), and the University of North Carolina (UNC) Medical Center.

The company began offering testing to clinicians in the first quarter of this year and expects volume to grow significantly over the next several months.

As part of the collaboration, UNC will use the firm's BarreGen assay to target molecular changes to predict resistance or relapse following ablation.

In PLOS this week: improved imputation, evolution of Vibrio cholerae isolates from recent outbreak, and more.

The approach could allow doctors to more accurately and more easily identify which patients are free from cancer after radiation treatment.

In Nucleic Acids Research this week: computational pipeline to find alternative transcription start sites, search for pathogenic mutations in Coats plus syndrome, and more.

Fresh Take on Ras

NPR reports on new work to find drugs to target the RAS cancer gene.

In PLOS this week: gene expression signatures in mouse breast cancer models, RNA sequencing study of Kaposi's sarcoma, and more.

The study will provide no-cost tumor sequencing and clinical trial matching to an estimated 100,000 patients with advanced cancers.

At HudsonAlpha's Genomic Medicine Conference University of North Carolina's Anya Prince discussed insurance coverage of genetic tests and preventive care.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.